Mda mb 453

Manufactured by BNCC

Sourced in China

MDA-MB-453 is a human breast adenocarcinoma cell line derived from a pleural effusion of a patient with metastatic breast cancer. The cells exhibit an epithelial-like morphology and are estrogen receptor (ER) and progesterone receptor (PR) negative. MDA-MB-453 cells are commonly used in breast cancer research as a model system.

Automatically generated - may contain errors

Lab products found in correlation

Mcf 7, by BNCC (4 mentions) Mda mb 231, by BNCC (3 mentions) Mcf 10a, by BNCC (3 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (2 mentions) Dulbecco modified eagle medium (dmem), by BNCC (1 mentions) Lip2000transfection reagent, by Biosharp (1 mentions) L 15 medium, by BNCC (1 mentions) Mir 18a 5p agomir, by GenePharma (1 mentions) Pcdna3, by GenePharma (1 mentions) Dmem medium, by Thermo Fisher Scientific (1 mentions) Lipofectamine 2000 transfection reagent, by Thermo Fisher Scientific (1 mentions) Mcf 10a, by Thermo Fisher Scientific (1 mentions) Mda mb 468, by BNCC (1 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (1 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)

3 protocols using mda mb 453

Profiling miR-18a-5p and HER2 in Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

To confirm the expression of miR−18a−5p and HER2 in BC cells and non-cancerous breast cells, human mammary epithelial cell line (MCF−10A) and human breast cancer cell lines (MDA-MB−231, MDA-MB−453, and MCF−7) were acquired from the BeNa Culture Collection (BNCC, China). MCF−10A cells were cultured in MEGM (BNCC), MCF−7 cells in DMEM (BNCC), while MDA-MB−453 and MDA-MB−231 cells were cultured in L−15 medium (BNCC). 10% fetal bovine serum (FBS; BNCC) was added to the culture medium and the cells were maintained at 37°C and 5% CO₂.
The agomiR NC, mimic negative control (NC), miR−18a−5p mimic, and miR−18a−5p agomiR were obtained from GenePharma (China). HER2 overexpression vectors and empty vectors were constructed using pcDNA3.1, obtained from GenePharma (China). Lip2000Transfection Reagent (Biosharp, China) was used to transfect the recombinant plasmids listed above into both MDA-MB−231 and MCF−7 cells. Cell transfection was performed for 48 h and assessed by qPCR analysis.

Liu Y, & Yang H. (2023). MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway. Cancer Biology & Therapy, 24(1), 2224512.

+ Open protocol

+ Expand

Establishment of paclitaxel-resistant breast cancer cell lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human TNBC cell lines (MDA-MB-453 and MCF7) were purchased from BeNa Culture Collection (Beijing, China), All cells were regularly authenticated using short tandem repeat (STR) DNA profiling and tested to confirm that they were mycoplasma contamination-free. The above cells were maintained in the DMEM medium (Gibco, USA) containing 10% fetal bovine serum (FBS, Gibco) under the conditions with 5% CO₂ atmosphere at 37°C. In addition, according to the experimental protocols recorded in our previous work (42 (link)), the paclitaxel-resistant MDA-MB-453/PTX and MCF7/PTX cell lines was established by treating the parental paclitaxel-sensitive BC cells with continuous paclitaxel treatment in a step-wise manner. The PR-BC cells were maintained in the DMEM medium (Gibco, USA) containing 10% fetal bovine serum, and the PR-BC cells at passage 2 to 4 with paclitaxel-resistant properties were used in this study. Moreover, the vectors for gp96 overexpression/downregulation and p53 overexpression were synthesized by Sangon Biotech (Shanghai, China), which were delivered into the TNBC cells by using the Lipofectamine 2000 transfection reagent (Invitrogen, USA). Moreover, the PS-BC cells were exposed to the hypoxic environment (0.2% oxygen, 5% CO₂, and 37°C) for three days to establish the hypoxic PS-BC cell models as previously described (43 (link)).

Tian T., Han J., Huang J., Li S, & Pang H. (2021). Hypoxia-Induced Intracellular and Extracellular Heat Shock Protein gp96 Increases Paclitaxel-Resistance and Facilitates Immune Evasion in Breast Cancer. Frontiers in Oncology, 11, 784777.

+ Open protocol

+ Expand

Establishing Paclitaxel-Resistant Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human breast epithelial cell line MCF-10A and human BC cell lines (MDA-MB-468, MDA-MB-453, MCF-7 and MDA-MB-231) were obtained from BeNa Culture Collection (Beijing, China). Human BC cells were cultivated in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Carlsbad, CA, USA) added with 10% fetal bovine serum (FBS; Gibco), 100 units/mL penicillin and 100 μg/mL streptomycin. MCF-10A cells were cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640, Gibco) supplemented with 10% FBS (Gibco) and 10% penicillin (100 U/mL)-streptomycin (100 μg/mL). All cells were grown in a 37°C, 5% CO₂ humidified incubator.
PTX was obtained from Sigma (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO; Sigma). The PTX-resistant BC cell lines, MCF-7/PTX and MDA-MB-231/PTX, were established by treating parental MCF-7 and MDA-MB-231 cells with increased concentration of PTX.22 (link)

Yang W., Gong P., Yang Y., Yang C., Yang B, & Ren L. (2020). Circ-ABCB10 Contributes to Paclitaxel Resistance in Breast Cancer Through Let-7a-5p/DUSP7 Axis. Cancer Management and Research, 12, 2327-2337.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!